Medzhitov R, Janeway CA: Innate immunity: the virtues of a nonclonal system of recognition. Cell. 1997, 91: 295-8. 10.1016/S0092-8674(00)80412-2.
Article
CAS
Google Scholar
Cristofaro P, Opal SM: Role of Toll-like receptors in infection and immunity: clinical implications. Drugs. 2006, 66: 15-29. 10.2165/00003495-200666010-00002.
Article
CAS
Google Scholar
Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet. 2005, 365: 63-78. 10.1016/S0140-6736(04)17667-8.
Article
CAS
Google Scholar
Andreakos E, Foxwell B, Feldmann M: Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?. Immunol Rev. 2004, 202: 250-65. 10.1111/j.0105-2896.2004.00202.x.
Article
CAS
Google Scholar
Schimke J, Mathison J, Morgiewicz J, Ulevitch RJ: Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci USA. 1998, 95: 13875-80. 10.1073/pnas.95.23.13875.
Article
CAS
Google Scholar
Meng G, Rutz M, Schiemann M, Metzger J, Grabiec A, Schwandner R, Luppa PB, Ebel F, Busch DH, Bauer S, Wagner H, Kirschning CJ: Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest. 2004, 113: 1473-81.
Article
CAS
Google Scholar
Kanzler H, Barrat FJ, Hessel EM, Coffman RL: Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007, 13: 552-9. 10.1038/nm1589.
Article
CAS
Google Scholar
Caron de Fromentel C, Gruel N, Venot C, Debussche L, Conseiller E, Dureuil C, Teillaud JL, Tocque B, Bracco L: Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene. 1999, 18: 551-7. 10.1038/sj.onc.1202338.
Article
CAS
Google Scholar
Tse E, Rabbitts TH: Intracellular antibody-caspase-mediated cell killing: an approach for application in cancer therapy. Proc Natl Acad Sci USA. 2000, 97: 12266-71. 10.1073/pnas.97.22.12266.
Article
CAS
Google Scholar
Wheeler YY, Chen SY, Sane DC: Intrabody and intrakine strategies for molecular therapy. Mol Ther. 2003, 8: 355-66. 10.1016/S1525-0016(03)00183-7.
Article
CAS
Google Scholar
Cao T, Heng BC: Intracellular antibodies (intrabodies) versus RNA interference for therapeutic applications. Ann Clin Lab Sci. 2005, 35: 227-9.
CAS
Google Scholar
Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G: Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005, 11: 263-70. 10.1038/nm1191.
Article
CAS
Google Scholar
Boldicke T: Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J Cell Mol Med. 2007, 11: 54-70. 10.1111/j.1582-4934.2007.00002.x.
Article
Google Scholar
Jendreyko N, Popkov M, Beerli RR, Chung J, McGavern DB, Rader C, Barbas CF: Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J Biol Chem. 2003, 278: 47812-9. 10.1074/jbc.M307002200.
Article
CAS
Google Scholar
Popkov M, Jendreyko N, McGavern DB, Rader C, Barbas CF: Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res. 2005, 65: 972-81.
CAS
Google Scholar
Poznansky MC, Foxall R, Mhashilkar A, Coker R, Jones S, Ramstedt U, Marasco W: Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum Gene Ther. 1998, 9: 487-96. 10.1089/hum.1998.9.4-487.
Article
CAS
Google Scholar
Swan CH, Buhler B, Steinberger P, Tschan MP, Barbas CF, Torbett BE: T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther. 2006, 13: 1480-92. 10.1038/sj.gt.3302801.
Article
CAS
Google Scholar
Richardson JH, Sodroski JG, Waldmann TA: Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the a subunit of the receptor. Proc Natl Acad Sci. 1995, 92: 3137-3141. 10.1073/pnas.92.8.3137.
Article
CAS
Google Scholar
Busch A, Marasco WA, Doebis C, Volk HD, Seifert M: MHC class I manipulation on cell surfaces by gene transfer of anti-MHC class I intrabodies-a tool for decreased immunogenicity of allogeneic tissue and cell transplants. Methods. 2004, 34: 240-249. 10.1016/j.ymeth.2004.03.017.
Article
CAS
Google Scholar
Tragoolpua K, Intasai N, Kasinrerk W, Mai S, Yuan Y, Tayapiwatana C: Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cells. BMC Biotechnol. 2008, 8: 1-13. 10.1186/1472-6750-8-5.
Article
Google Scholar
Strebe N, Guse A, Schüngel M, Schirrmann T, Hafner M, Jostock T, Hust M, Müller W, Dübel S: Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies. J Immunol Methods. 2009, 341: 30-40. 10.1016/j.jim.2008.10.012.
Article
CAS
Google Scholar
Lewis MJ, Pelham HRB: Ligand-induced redistribution of a human KDEL receptor from the Golgi complex to the endoplasmic reticulum. Cell. 1992, 68: 353-64. 10.1016/0092-8674(92)90476-S.
Article
CAS
Google Scholar
Donoso G, Herzog V, Schmitz A: Misfolded BiP is degraded by a proteasome-independent endoplasmic-reticulum-associated degradation pathway. Biochem J. 2005, 387: 897-903. 10.1042/BJ20041312.
Article
CAS
Google Scholar
Meusser B, Hirsch C, Jarosch E, Sommer T: ERAD: the long road to destruction. Nat Cell Biol. 2005, 7: 766-72. 10.1038/ncb0805-766.
Article
CAS
Google Scholar
Schmitz A, Schneider A, Kummer MP, Herzog V: Endoplasmic reticulum-localized amyloid beta-peptide is degraded in the cytosol by two distinct degradation pathways. Traffic. 2004, 5: 89-101. 10.1111/j.1600-0854.2004.00159.x.
Article
CAS
Google Scholar
van Anken E, Braakman I: Versatility of the endoplasmic reticulum protein folding factory. Crit Rev Biochem Mol Biol. 2005, 40: 191-228. 10.1080/10409230591008161.
Article
CAS
Google Scholar
Uematsu S, Akira S: The role of Toll-like receptors in immune disorders. Expert Opin Biol Ther. 2006, 6: 203-14. 10.1517/14712598.6.3.203.
Article
CAS
Google Scholar
Kaner RJ, Worgall S, Leopold PL, Stolze E, Milano E, Hidaka C, Ramalingam R, Hackett NR, Singh R, Bergelson J, Finberg R, Falck-Pedersen E, Crystal RG: Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of expression of the coxsackie/adenovirus receptor. Am J Respir Cell Mol Biol. 1999, 20: 361-370.
Article
CAS
Google Scholar
Loo Van de FAJ, de Hooge ASK, Smeets RL, Bakker AC, Bennink MB, Arntz OJ, Joosten LAB, van Beuningen HM, Kraan van der PK, Varley AW, Berg van den WB: An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint. Gene Ther. 2004, 11: 581-590. 10.1038/sj.gt.3302182.
Article
Google Scholar
Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK, Rodgers JR, Lee B: Toll-like Receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Am Soc Gene Ther. 2007, 15: 378-385.
Article
CAS
Google Scholar
Haisma HJ, Boesjes M, Beerens AM, Strate van der BWA, Curiel DT, Plüddemann A, Gordon S, Bellu AR: Scavenger Receptor A: A new route for adenovirus 5. Mol Pharm. 2009, 6: 366-374. 10.1021/mp8000974.
Article
CAS
Google Scholar
Meier O, Greber UF: Adenovirus endocytosis. J Gene Med. 2003, 5: 451-462. 10.1002/jgm.409.
Article
CAS
Google Scholar
Brantl S: Antisense-RNA regulation and RNA interference. Biochim Biophys Acta. 2002, 1575: 15-25.
Article
CAS
Google Scholar
Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003, 4: 346-58. 10.1038/nrg1066.
Article
CAS
Google Scholar
Lavillette D, Russell SJ, Cosset FL: Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotechnol. 2001, 12: 461-6. 10.1016/S0958-1669(00)00246-9.
Article
CAS
Google Scholar
Glasgow JN, Bauerschmitz GJ, Curiel DT, Hemminki A: Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther. 2004, 4: 1-14. 10.2174/1566523044577997.
Article
CAS
Google Scholar
Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, Michel BA, Seger RA, Gay S, Lauener RP: Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol. 2003, 162: 1221-7.
Article
CAS
Google Scholar
Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009, 457: 102-106. 10.1038/nature07623.
Article
CAS
Google Scholar
Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strobe W: Current Protocols in Immunology. 1990, NY: John Wiley & Sons, Inc
Google Scholar
Spiller S, Dreher S, Meng G, Grabiec A, Thomas W, Hartung T, Pfeffer K, Hochrein H, Brade H, Bessler W, Wagner H, Kirschning CJ: Cellular recognition of trimyristoylated peptide or enterobacterial lipopolysaccharide via both TLR2 and TLR4. J Biol Chem. 2007, 282: 13190-8. 10.1074/jbc.M610340200.
Article
CAS
Google Scholar
Pope AR, Embleton MJ, Mernaugh R: Construction and use of antibody gene repertoires. Antibody Engineering. Edited by: McCafferty J, Hoogenboom HR, Chiswell DJ. 1996, Oxford University Press, Oxford, New York, Tokyo, 1-40.
Google Scholar
Böldicke T, Tesar M, Griesel C, Rohde M, Gröne HJ, Waltenberger J, Kollet O, Lapidot T, Yayon A, Weich H: Anti-VEGFR-2 scFvs for cell isolation. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1) on the surface of primary endothelial cells and preselected CD34+ cells from cord blood. Stem cells. 2001, 19: 24-36. 10.1634/stemcells.19-1-24.
Article
Google Scholar
Mayer H, Bertram H, Lindenmaier W, Korff T, Weber H, Weich H: Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. J Cell Biochem. 2005, 95: 827-39. 10.1002/jcb.20462.
Article
CAS
Google Scholar
Graham FL, Prevec L: Methods for construction of adenovirus vectors. Mol Biotechnol. 1995, 3: 207-20.
Article
CAS
Google Scholar
Boldicke T, Weber H, Mueller PP, Barleon B, Bernal M: Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR). J Immunol Methods. 2005, 300: 146-59. 10.1016/j.jim.2005.03.007.
Article
Google Scholar
Meng G, Grabiec A, Vallon M, Ebe B, Hampel S, Bessler W, Wagner H, Kirschning CJ: Cellular recognition of tri-/di-palmitoylated peptides is independent from a domain encompassing the N-terminal seven leucin-rich repaet (LRR)/LRR-like motifs of TLR2. J Biol Chem. 2003, 278: 39822-39829. 10.1074/jbc.M304766200.
Article
CAS
Google Scholar